ISDA

Deposition Date 2019-01-15

Release Date 2019-10-23

Last Version Date 2024-10-23

Entry Detail

PDB ID:

6J6M

Keywords:

Transferase/Transferase inhibitor

Title:

Co-crystal structure of BTK kinase domain with Zanubrutinib

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.25 Å

R-Value Free:

0.16

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 2 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase BTK
Gene (Uniprot):BTK
Chain IDs:A
Chain Length:269
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

BA0

IMD

Primary Citation

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Guo, Y, Liu, Y, Hu, N, Yu, D, Zhou, C, Shi, G, Zhang, B, Wei, M, Liu, J, Luo, L, Tang, Z, Song, H, Guo, Y, Liu, X, Su, D, Zhang, S, Song, X, Zhou, X, Hong, Y, Chen, S, Cheng, Z, Young, S, Wei, Q, Wang, H, Wang, Q, Lv, L, Wang, F, Xu, H, Sun, H, Xing, H, Li, N, Zhang, W, Wang, Z, Liu, G, Sun, Z, Zhou, D, Li, W, Liu, L, Wang, L, Wang, Z.Show

J.Med.Chem. 62 7923 7940 (2019)

PMID: 31381333 DOI: 10.1021/acs.jmedchem.9b00687

Abstact

Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.

Legend

Protein

Chemical

Disease

Primary Citation of related structures